Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 3 examiners • 0 of 5 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Recode Therapeutics Inc. has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters are handled by 3 distinct examiners across 3 distinct art units, creating a prosecution portfolio with multiple examination relationships and more pending work than examiner assignments.
HAGHIGHATIAN, MINA is the busiest examiner, with 3 pending matters. That assignment represents the principal concentration of the current docket, while the remaining actions are associated with other examination paths. Counsel can prioritize consistency across the matters before HAGHIGHATIAN while separately tailoring responses to the other art units and examiners.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (20%) |
| Double-patenting + other | 3 (60%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAGHIGHATIAN, MINA | 3 | 46.0% | +39.4% |
| RONEY, CELESTE A | 1 | 63.0% | +17.4% |
| KONOPKA, CATHERINE ANNE | 1 | 57.5% | +66.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18283143 | POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS, AND METHODS OF USE THEREOF | KONOPKA, CATHERINE ANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18780382 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RONEY, CELESTE A | — |
| 18596151 | POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS, AND METHODS OF USE THEREOF | HAGHIGHATIAN, MINA | — |
| 18596141 | POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS, AND METHODS OF USE THEREOF | HAGHIGHATIAN, MINA | — |
| 18596148 | POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS, AND METHODS OF USE THEREOF | HAGHIGHATIAN, MINA | — |
| 18283143 | POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS, AND METHODS OF USE THEREOF | KONOPKA, CATHERINE ANNE | — |
| Art Unit | Apps |
|---|---|
| 1616 | 3 |
| 1612 | 1 |
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18780382 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RONEY, CELESTE A | 1612 | DP | Non-Final OA | — | Pending | Jul 22, 2024 |
| 18596151 | POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS, AND METHODS OF USE THEREOF | HAGHIGHATIAN, MINA | 1616 | §103DP | Non-Final OA | — | Pending | Mar 05, 2024 |
| 18596141 | POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS, AND METHODS OF USE THEREOF | HAGHIGHATIAN, MINA | 1616 | §103DP | Non-Final OA | — | Pending | Mar 05, 2024 |
| 18596148 | POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS, AND METHODS OF USE THEREOF | HAGHIGHATIAN, MINA | 1616 | §103DP | Non-Final OA | — | Pending | Mar 05, 2024 |
| 18283143 | POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS, AND METHODS OF USE THEREOF | KONOPKA, CATHERINE ANNE | 1635 | §102§103 | Non-Final OA | — | Pending | Sep 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRecode Therapeutics Inc. has 5 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Mina Haghighatian has the most, with 3 of Recode Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
